Deferoxamine promotes MDA-MB-231 cell migration and invasion through increased ros-dependent HIF-1α accumulation

Cellular Physiology and Biochemistry

Volumn 33, Issue 4, 2014, Pages 1036-1046

  Liu, Yiping ^a,c   Cui, Yongfeng ^b   Shi, Miao ^b   Zhang, Qiang ^b   Wang, Qiang ^a   Chen, Xiaodong ^a,b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b INNER MONGOLIA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Beijing Municipal Public Security Bureau   (China)

Author keywords

Breast cancer; Deferoxamine; Extracellular signal regulated kinase 1 2; Hypoxia inducible factor 1 ; Reactive oxygen species

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DEFEROXAMINE; DIPHENYLIODONIUM SALT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VASCULOTROPIN; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; CATION; FLAVONOID; SIDEROPHORE;

ARTICLE; BREAST CANCER; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IRON CHELATION; METASTASIS; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; WOUND HEALING; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; TOXICITY; TUMOR CELL LINE; BIOACCUMULATION; BREAST CANCER CELL LINE; FEMALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR INVASION;

CELL LINE, TUMOR; CELL MOVEMENT; DEFEROXAMINE; FLAVONOIDS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NADPH OXIDASE; ONIUM COMPOUNDS; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SIDEROPHORES; UP-REGULATION;

EID: 84897967408     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000358674     Document Type: Article

References (45)

1. Kwok JC, Richardson DR: The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol 2002;42:65-78.
2. Rehman S, Husnain SM: A Probable Risk Factor of Female Breast Cancer: Study on Benign and Malignant Breast Tissue Samples. Biol Trace Elem Res 2014;157:24-29.
3. Cui Y, Vogt S, Olson N, Glass AG, Rohan TE: Levels of zinc, selenium, calcium, and iron in benign breast tissue and risk of subsequent breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1682-1685.
4. Singh M, Mugler K, Hailoo DW, Burke S, Nemesure B, Torkko K, Shroyer KR: Differential expression of transferrin receptor (TfR) in a spectrum of normal to malignant breast tissues: implications for in situ and invasive carcinoma. Appl Immunohistochem Mol Morphol 2011;19:417-423.
5. Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM: Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat 2010;119:283-293.
6. Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VF, Beland FA, Pogribny IP: Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 2011;126:63-71.
7. Pahl PM, Horwitz MA, Horwitz KB, Horwitz LD: Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. Breast Cancer Res Treat 2001;69:69-79.
8. Kulp KS, Vulliet PR: Mimosine blocks cell cycle progression by chelating iron in asynchronous human breast cancer cells. Toxicol Appl Pharmacol 1996;139:356-364.
9. Hoke EM, Maylock CA, Shacter E: Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic Biol Med 2005;39:403-411.
10. Jiang XP, Wang F, Yang DC, Elliott RL, Head JF: Induction of apoptosis by iron depletion in the human breast cancer MCF-7 cell line and the 13762NF rat mammary adenocarcinoma in vivo. Anticancer Res 2002;22:2685-2692.
11. Reddel RR, Hedley DW, Sutherland RL: Cell cycle effects of iron depletion on T-47D human breast cancer cells. Exp Cell Res 1985;161:277-284.
12. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S: Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 2008;172:738-747.
13. Salnikow K, Donald SP, Bruick RK, Zhitkovich A, Phang JM, Kasprzak KS: Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 2004;279:40337-40344.
14. Bertout JA, Patel SA, Simon MC: The impact of O2 availability on human cancer. Nat Rev Cancer 2008;8:967-975.
15. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003;97:1573-1581.
16. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G, Austrian Breast and Colorectal Cancer Study Group: Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831-1837.
17. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, Iwase H: Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 2008;110:465-475.
18. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, Schumacker PT: Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J Biol Chem 2000;275:25130-25138.
19. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, Schumacker PT: Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005;1:401-408.
20. Schroedl C, McClintock DS, Budinger GR, Chandel NS: Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2002;283:L922-L931.
21. Biswas S, Gupta MK, Chattopadhyay D, Mukhopadhyay CK: Insulin-induced activation of hypoxia-inducible factor-1 requires generation of reactive oxygen species by NADPH oxidase. Am J Physiol Heart Circ Physiol 2007;292:H758-H766.
22. Fandrey J, Frede S, Jelkmann W: Role of hydrogen peroxide in hypoxia-induced erythropoietin production. Biochem J 1994;303:507-510.
23. Haddad JJ, Land SC: A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha. FEBS Lett 2001;505:269-274.
24. Shi YH, Wang YX, Bingle L, Gong LH, Heng WJ, Li Y, Fang WG: In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways. J Pathol 2005;205:530-536.
25. Callapina M, Zhou J, Schmid T, Köhl R, Brüne B: NO restores HIF-1alpha hydroxylation during hypoxia: role of reactive oxygen species. Free Radic Biol Med 2005;39:925-936.
26. Wartenberg M, Ling FC, Müschen M, Klein F, Acker H, Gassmann M, Petrat K, Pütz V, Hescheler J, Sauer H: Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 2003;17:503-505.
27. Vaux EC, Metzen E, Yeates KM, Ratcliffe PJ: Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood 2001;98:296-302.
28. Zhang W, Wu Y, Yan Q, Ma F, Shi X, Zhao Y, Peng Y, Wang J, Jiang B: Deferoxamine enhances cell migration and invasion through promotion of HIF-1α expression and epithelial-mesenchymal transition in colorectal cancer. Oncol Rep 2014;31:111-116.
29. Goyal P, Weissmann N, Grimminger F, Hegel C, Bader L, Rose F, Fink L, Ghofrani HA, Schermuly RT, Schmidt HH, Seeger W, Hänze J: Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic Biol Med 2004;36:1279-1288.
30. Adachi Y, Shibai Y, Mitsushita J, Shang WH, Hirose K, Kamata T: Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. Oncogene 2008;27:4921-4932.
31. Rathnasamy G, Ling EA, Kaur C. Hypoxia inducible factor-1α mediates iron uptake which induces inflammatory response in amoeboid microglial cells in developing periventricular white matter through MAP kinase pathway. Neuropharmacology 2014;77:428-440.
32. Martínez-Romero R, Martínez-Lara E, Aguilar-Quesada R, Peralta A, Oliver FJ, Siles E: PARP-1 modulates deferoxamine-induced HIF-1alpha accumulation through the regulation of nitric oxide and oxidative stress. J Cell Biochem 2008;104:2248-2260.
33. Wu Y, Li X, Xie W, Jankovic J, Le W, Pan T: Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int 2010;57:198-205.
34. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, Charpin C: Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005;116:734-739.
35. Schroedl C, McClintock DS, Budinger GR, Chandel NS: Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2002;283:L922-L931.
36. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, Schumacker PT: Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005;1:401-408.
37. Mu D, Chang YS, Vexler ZS, Ferriero DM: Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp Neurol 2005;195:407-415.
38. Lee YS, Wurster RD: Deferoxamine-induced cytotoxicity in human neuronal cell lines: protection by free radical scavengers. Toxicol Lett 1995;78:67-71.
39. Becton DL, Bryles P: Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 1988;48:7189-7192.
40. Klebanoff SJ, Waltersdorph AM, Michel BR, Rosen H: Oxygen-based free radical generation by ferrous ions and deferoxamine. J Biol Chem 1989;264:19765-19771.
41. Echiburú-Chau C, Roy D, Calaf GM: Metastatic suppressor CD44 is related with oxidative stress in breast cancer cell lines. Int J Oncol 2011;39:1481-1489.
42. Shi YH, Wang YX, Bingle L, Gong LH, Heng WJ, Li Y, Fang WG: In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways. J Pathol 2005;205:530-536.
43. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T, Hay N: Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008;14:458-470.
44. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouysségur J: Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J 1999;18:664-674.
45. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J: MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 2003;278:14013-14019.